Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment

Critical Care Clinical Trial

Official title:

Oxidative Stress and Microcirculation in Patient With Hepatic Failure Undergoing Liver Support Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00772252
• Other study ID #: 200806004R
• Status: Recruiting
• Phase: N/A
• First received: October 14, 2008
• Last updated: June 28, 2010
• Start date: August 2008
• Est. completion date: December 2010

Study information

• Verified date: June 2010
• Source: National Taiwan University Hospital
• Contact: Yu-Chang Yeh
• Phone: 0968661829
• Email: tonyyeh[@]ntuh.gov.tw
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Observational

Clinical Trial Summary

Background: In patients undergoing hemodialysis or hemofiltration will suffer from the injury of reactive oxidative species. Oxidative stress will affect cell membrane, protein, and DNA. It will damage the cell and result in organ dysfunction. We believe that in patients, who have acute hepatic failure, undergoing plasma exchange or Molecular Absorbent Recirculating System for bridge therapy will suffer from the injury of reactive oxidative species, too. It will damage the kidney, lung, cerebral cortex, and other organs. It may result in death before the recovery of liver function or undergoing liver transplantation.

Aims: 1. Investigate the severity of oxidative stress and risk factors of high oxidative stress in acute hepatic failure patient undergoing plasma exchange or Molecular Absorbent Recirculating System. 2. Investigate the microcirculation status and risk factors in acute hepatic failure patient undergoing plasma exchange or Molecular Absorbent Recirculating System. 3. Study the relationship between oxidative stress and microcirculation status. 4. Study the correlation between oxidative stress and prognosis. 5. Study the correlation between microcirculation status and prognosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2010
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age > 18 years old

2. Patients with acute deterioration on Chronic liver failure, who required liver support treamtment

3. Patients with acute liver failure due to acute hepatitis, who reauired liver support treatment

4. Patients with acute liver dysfunction within 7 days after liver transplantation, who required liver support treatment

Exclusion Criteria:

1. Age > 70 years old

2. Cancer, not curable

3. Patients who had used of antioxidant therapy within 24 hours before study

4. Patients who had received hyperbaric oxygen therapy within 24 hours before study

5. Patients who had received peroxide treatment within 24 hours before study

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Critical Care
• Liver Failure

Intervention

Other:
• liver support treatment
plasma exchange for liver support treatment

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan,